share_log

Exicure | 10-Q: Q1 2024 Earnings Report

Exicure | 10-Q: Q1 2024 Earnings Report

Exicure | 10-Q:2024財年一季報
美股SEC公告 ·  06/18 04:32

牛牛AI助理已提取核心訊息

Exicure, a biotechnology company, reported a net loss of $829,000 for the first quarter of 2024, a significant improvement from the $4.4 million net loss in the same period of 2023. The company's revenue for the quarter was $500,000, a stark contrast to the previous year's first quarter, which saw no revenue. This revenue stems from a patent license agreement for a hepatitis treatment. Operating expenses decreased by 71% to $1.3 million, down from $4.5 million in the first quarter of 2023, primarily due to the suspension of research and development activities and a reduction in force announced in September 2022. As of March 31, 2024, Exicure's cash and cash equivalents stood at $0.4 million, down from $0.8 million at the end of 2023. The company's financial situation remains precarious, with...Show More
Exicure, a biotechnology company, reported a net loss of $829,000 for the first quarter of 2024, a significant improvement from the $4.4 million net loss in the same period of 2023. The company's revenue for the quarter was $500,000, a stark contrast to the previous year's first quarter, which saw no revenue. This revenue stems from a patent license agreement for a hepatitis treatment. Operating expenses decreased by 71% to $1.3 million, down from $4.5 million in the first quarter of 2023, primarily due to the suspension of research and development activities and a reduction in force announced in September 2022. As of March 31, 2024, Exicure's cash and cash equivalents stood at $0.4 million, down from $0.8 million at the end of 2023. The company's financial situation remains precarious, with a substantial doubt about its ability to continue as a going concern without securing additional funding in the near term. Exicure is actively exploring strategic alternatives, including potential partnerships and transactions in industries unrelated to its historical operations. The company has also experienced a change of control with CBI USA and its affiliate DGP acquiring a significant portion of its common stock. Exicure faces delisting from Nasdaq due to non-compliance with several listing requirements, including minimum bid price and stockholders' equity. The company has appealed the delisting determination and is awaiting a hearing scheduled for July 9, 2024.
生物技術公司Exicure報告稱,2024年第一季度淨虧損爲829,000美元,相比2023年同期的440萬美元淨虧損顯著改善。該季度該公司的營業收入爲50萬美元,與前年同期沒有營業收入形成鮮明對比。這一收入來自於一項針對肝炎的專利許可協議。營業費用減少了71%,從2023年第一季度的450萬美元降至130萬美元,主要是由於在2022年9月宣佈暫停研發活動和裁員。截至2024年3月31日,Exicure的現金及現金等價物爲0.4萬美元,較2023年年底的0.8萬美元下降。該公司的財務狀況仍然不穩定,存在重大疑慮,需要在短期內獲得額外資金才能繼續經營。Exicure正在積極探索戰略替代方案,包括...展開全部
生物技術公司Exicure報告稱,2024年第一季度淨虧損爲829,000美元,相比2023年同期的440萬美元淨虧損顯著改善。該季度該公司的營業收入爲50萬美元,與前年同期沒有營業收入形成鮮明對比。這一收入來自於一項針對肝炎的專利許可協議。營業費用減少了71%,從2023年第一季度的450萬美元降至130萬美元,主要是由於在2022年9月宣佈暫停研發活動和裁員。截至2024年3月31日,Exicure的現金及現金等價物爲0.4萬美元,較2023年年底的0.8萬美元下降。該公司的財務狀況仍然不穩定,存在重大疑慮,需要在短期內獲得額外資金才能繼續經營。Exicure正在積極探索戰略替代方案,包括潛在的合作伙伴和與其歷史業務無關的交易。該公司還經歷了與CBI USA及其附屬公司DGP獲得其普通股的重大變化。由於未遵守多個上市要求,包括最低買盤價和股東權益,Exicure面臨着從納斯達克除牌的風險。該公司已經上訴除牌決定,正在等待於2024年7月9日舉行的聽證會。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。